Adherium Accelerates U.S. RPM Rollout with Allergy Partners, Activates 70% Clinics
Adherium Limited has reached a pivotal commercial milestone by expanding its Remote Patient Monitoring program across 110 U.S. Allergy Partners clinics, activating nearly 70% of the network and onboarding close to 700 patients in six months.
- Rapid expansion to 110 Allergy Partners clinics nationwide
- Nearly 70% of clinics activated on Adherium’s RPM platform
- Approximately 700 patients onboarded and monitored in six months
- Supports goal of 4,000 active U.S. patients by 2025
- Establishes scalable recurring revenue via fee-for-service model
A Commercial Turning Point
Adherium Limited (ASX, ADR), a global leader in digital respiratory management, has announced a significant commercial inflection point in its collaboration with Allergy Partners, one of the largest allergy and asthma networks in the United States. The partnership has evolved from a technology deployment agreement into a fully managed, revenue-generating Remote Patient Monitoring (RPM) program, marking a transition from proof-of-concept to proof-of-performance.
In under six months, Adherium has overseen the activation of nearly 70% of Allergy Partners’ 110 clinics, enrolling close to 700 patients onto its FDA-cleared Hailie® Smartinhaler® platform. This rapid rollout demonstrates the company’s operational capability to scale complex digital health solutions across a large, decentralized specialty network.
Driving Recurring Revenue and Patient Outcomes
The collaboration leverages a fee-for-service business model, where each activated clinic generates recurring revenue as patients are onboarded and monitored under reimbursable RPM and Remote Therapeutic Monitoring (RTM) codes. This creates a predictable and scalable revenue stream directly linked to clinical activation and patient engagement.
Allergy Partners’ CEO, Dr. William A. McCann, highlighted the clinical benefits, noting that the Hailie platform provides clinicians with real-time adherence data and early risk identification, which is transforming asthma and COPD care. This integration enables more proactive and personalized treatment, addressing long-standing challenges in patient adherence to controller therapies.
Momentum Towards 2025 Targets
Adherium’s progress with Allergy Partners supports its calendar year 2025 target of approximately 4,000 active patients across its U.S. RPM program and partner ecosystem. The company expects to activate five additional clinics by year-end, further solidifying its foothold in the U.S. digital respiratory market.
CEO Dawn Bitz emphasized that this milestone is just the beginning, with patient adoption growing steadily and operational traction providing the foundation for sustained commercial growth. The partnership also includes plans to enhance patient engagement through dedicated Hailie resources on Allergy Partners’ website, reinforcing the patient-centric approach.
Strategic Implications
This milestone underscores Adherium’s ability to convert innovative digital health technology into tangible commercial outcomes within a complex healthcare environment. As reimbursement frameworks for remote monitoring evolve, Adherium’s scalable model positions it well to capitalize on growing demand for connected respiratory care solutions.
Looking ahead, the company’s success with Allergy Partners may serve as a blueprint for expanding partnerships with other large specialty networks, potentially accelerating adoption and revenue growth in the U.S. and beyond.
Bottom Line?
Adherium’s rapid U.S. RPM expansion signals a new era of scalable digital respiratory care and recurring revenue growth.
Questions in the middle?
- How will reimbursement changes impact Adherium’s RPM revenue trajectory?
- What are the financial metrics behind patient onboarding and clinic activation?
- Can Adherium replicate this success with other large specialty networks?
